 Previous mega trials have demonstrated that lipid-lowering therapy with HMG-CoA reductase inhibitors in individuals with high risk of cardiovascular disease reduces the incidence of coronary heart disease. NCEP ATP-III has suggested the advantage of more intensive lipid lowering therapy with a goal of reducing LDL-C below 70 mgdL for such patients categorized as very high risk. In Japan, Japan Atherosclerosis Society JAS Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases 2002 have recommended that an LDL-C goal for patients with coronary heart disease CHD should be below 100 mgdL. However, there is no satisfactory evidence whether the investigators need to lower LDL-C level less than the 70mgdL or not in Japanese population. 